The Experts below are selected from a list of 153 Experts worldwide ranked by ideXlab platform
Unnop Jaisamrarn - One of the best experts on this subject based on the ideXlab platform.
-
a comparison of cycle control efficacy and side effects among healthy thai women between two low dose oral contraceptives containing 20 μg ethinylestradio1 75 μg gestodene meliane and 30 μg ethinylestradio1 75 μg gestodene gynera
Contraception, 2002Co-Authors: Surasak Taneepanichskul, R Kriengsinyot, Unnop JaisamrarnAbstract:The purpose of this study was to compare cycle control, efficacy and side effects of an oral contraceptive containing 20 μg ethinylestradiol and 75 μg gestodene, with a reference preparation containing 30 μg ethinylestradiol combined with 75 μg gestodene. From the study, it was demonstrated that the two regimens had no difference in cycle control, efficacy, and side effects. The occurrence of spotting and breakthrough bleeding was low and was not different between these two preparations. The most common adverse events in both treatment groups were nausea, vomiting, dizziness, and Chloasma. There were no statistically significant change in body weight and blood pressure in both groups at the end of study. It is concluded that both preparations are good cycle control, reliable and low side effects oral contraceptives.
Surasak Taneepanichskul - One of the best experts on this subject based on the ideXlab platform.
-
a comparison of cycle control efficacy and side effects among healthy thai women between two low dose oral contraceptives containing 20 μg ethinylestradio1 75 μg gestodene meliane and 30 μg ethinylestradio1 75 μg gestodene gynera
Contraception, 2002Co-Authors: Surasak Taneepanichskul, R Kriengsinyot, Unnop JaisamrarnAbstract:The purpose of this study was to compare cycle control, efficacy and side effects of an oral contraceptive containing 20 μg ethinylestradiol and 75 μg gestodene, with a reference preparation containing 30 μg ethinylestradiol combined with 75 μg gestodene. From the study, it was demonstrated that the two regimens had no difference in cycle control, efficacy, and side effects. The occurrence of spotting and breakthrough bleeding was low and was not different between these two preparations. The most common adverse events in both treatment groups were nausea, vomiting, dizziness, and Chloasma. There were no statistically significant change in body weight and blood pressure in both groups at the end of study. It is concluded that both preparations are good cycle control, reliable and low side effects oral contraceptives.
N Dusitsin - One of the best experts on this subject based on the ideXlab platform.
-
effectiveness of norplant implants among thai women in bangkok
Contraception, 1996Co-Authors: Sumana Chompootaweep, E Kochagarn, S Sirisumpan, J Tangusaha, B Theppitaksak, N DusitsinAbstract:Abstract The purpose of the study was to evaluate the efficacy, acceptability, side effects and continuation rates of the implant system in Thai women. A five-year clinical study of 308 women receiving Norplant ® -6 implants in Bangkol was conducted. Acceptors' mean age was 29 years, and mean number of children was about two. More than half of the users (63%) finished primary school. The cumulative continuation rates for Norplant ® implants at irst, second, third, fourth and fifth years were, respectively, 98%, 91%, 83%, 78% and 71%. Eight out of a total of eleven pregnancies occurred in the fourth and fifth year of use. The cumulative pregnancy rate was 1.1% for the third year, 2.0% for the fourth year and 4.2% for the fifth year. Desire for future pregnancy was the leading cause for termination of Norplant ® implants use. The five-year cumulative termination rate for planned pregnancy was 9.2%. Disruption of menstrual rhythm, particularly increased bleeding, was the other main reason for termination; however, the prevalence of menstrual irregularities appeared to diminish with time. The cumulative termination rate for menstrual irregularities in the fifth year of the study was 4.4%. The complaints of "other medical reasons" for removal of Norplant ® implants were acne, severe headache, and Chloasma. The five-year cumulative termination rate for other personal reasons was 7.9%. These personal reasons were husband having vasectomy, husband objection and divorce. It can be seen from this five-year study that Norplant ® implants are well accepted by Thai women. However, the efficacy in preventing pregnancy was not acceptable during the fourth and fifth year of use in this study, which was different from results of other international studies.
A Rougier - One of the best experts on this subject based on the ideXlab platform.
-
evaluation of the effectiveness of a broad spectrum sunscreen in the prevention of Chloasma in pregnant women
Journal of The European Academy of Dermatology and Venereology, 2007Co-Authors: H Lakhdar, K Zouhair, K Khadir, A Essari, A Richard, Sophie Seite, A RougierAbstract:Background Chloasma, or melasma, is a pigmentary disorder that can affect between 50% and 70% of pregnant women. During pregnancy, Chloasma does not require any particular treatment beside the use of an effective sunscreen and avoiding the use of any photosensitizing products or inappropriate skin care routine. However, there exist very few studies related to the benefits of sunscreens to prevent this dermatosis. Objective The aim of this study was to assess the role of a broad-spectrum sunscreen in the prevention and treatment of Chloasma in pregnant women. Methods We tested the effectiveness and tolerance of a sunscreen composition (SPF 50+, UVA-PF 28) during a 12-month clinical trial on 200 parturients. Results The 'excellent' tolerance of the sunscreen under evaluation was confirmed. Out of 185 patients who completed the study, only five new cases of Chloasma were noted, an occurrence of 2.7%, which is much lower than the 53% previously observed in an usual condition study (same investigators, same geographical area and same time frame). In addition, the clinical effectiveness of the evaluated sunscreen was judged 'excellent' by the majority of parturients and by the research dermatologists during all the consultations. It is also worth noting that at 6 months, a clinical improvement was observed in 8 out of 12 volunteers who were affected by a pre-existing Chloasma observed during their inclusion visit. Colorimetric measurements showed that, at the end of their pregnancy, the parturients' skin was, on average, significantly lightened (increase of parameter L* in 38% cases) and less pigmented (reduction of parameter b* in 50% cases); thus, resulting in a significantly lighter skin colour (increase of ITA degrees in 69% cases) compared to their inclusion visit. Conclusions This study clearly demonstrates the effectiveness of the well-tolerated broad-spectrum sunscreen evaluated, in the prevention of the development of Chloasma in pregnant women.
R Kriengsinyot - One of the best experts on this subject based on the ideXlab platform.
-
a comparison of cycle control efficacy and side effects among healthy thai women between two low dose oral contraceptives containing 20 μg ethinylestradio1 75 μg gestodene meliane and 30 μg ethinylestradio1 75 μg gestodene gynera
Contraception, 2002Co-Authors: Surasak Taneepanichskul, R Kriengsinyot, Unnop JaisamrarnAbstract:The purpose of this study was to compare cycle control, efficacy and side effects of an oral contraceptive containing 20 μg ethinylestradiol and 75 μg gestodene, with a reference preparation containing 30 μg ethinylestradiol combined with 75 μg gestodene. From the study, it was demonstrated that the two regimens had no difference in cycle control, efficacy, and side effects. The occurrence of spotting and breakthrough bleeding was low and was not different between these two preparations. The most common adverse events in both treatment groups were nausea, vomiting, dizziness, and Chloasma. There were no statistically significant change in body weight and blood pressure in both groups at the end of study. It is concluded that both preparations are good cycle control, reliable and low side effects oral contraceptives.